Read more about the new pill for delivering Parkinson’s medication here.
Could a single daily pill deliver Parkinson’s medication?
News
Author: Simge Eva DoganPublished: 1 October 2020
Prep:
Cook:
Serves:

Scientists at Nanyang Technological University, Singapore, have developed a new pill that could be used to slowly deliver medication over a 24-hour period to people living with Parkinson’s disease.
They hope that delivering Parkinson’s medication in this way could help manage symptoms which can occur when people experience ‘off’ periods between taking medications. A team at the university’s startup LiberaTx is now commercialising the technology and planning clinical trials to test the efficacy of the pill.
Joachim Loo (pictured left), associate professor at the university and founder of LiberaTx, said: “We hope that […] reducing dosage to just once-a-day would greatly improve patient compliance, lower the pill burden of these patients, while alleviating the ‘off’ periods that these patients experience. Achieving this would greatly improve quality of life for the patient.”
If the pill is proven successful for treating Parkinson’s disease, it may also be used for treating other conditions that require taking multiple drugs daily.
Lead image credit: NTU Singapore
For more information on the latest Parkinson’s research please visit the EPDA website.
Read more:
New tool could support “faster diagnosis” of Parkinson’s disease psychosis
Has Covid-19 impacted access to Parkinson’s medication?
Last Month
Next Month
Share this story
Related articles

PD in Practice
Tips and tricks: how Parkinson’s patients can discover their own coping strategies
Bouncing a ball or riding a bike could help your symptoms
READ MORE
In my country
Powerful partnership promotes Parkinson’s rehab in Jerusalem
A partnership helped to expand exercise and therapy sessions in Jerusalem
READ MORE
Europe
Copenhagen carnival: campaigners and cyclists join forces for Unity Walk
Copenhagen’s streets to be overrun with Parkinson’s campaigners
READ MORE
Comments